Home > Dermatology > EADV 2022 > IL4/IL13 blockade shows remarkable efficacy in prurigo nodularis

IL4/IL13 blockade shows remarkable efficacy in prurigo nodularis

Presented By
Prof. Gil Yosipovitch, University of Miami, FL, USA
Conference
EADV 2022
Trial
Phase 2, LIBERTY-PN PRIME
In a phase 2 trial presented as a late breaker, patients with prurigo nodularis treated with dupilumab showed a remarkable itch improvement from baseline to week 24. This is already the second phase 2 trial showing that dupilumab reduced both pruritus and the number of prurigo nodularis lesions. Following the positive results in prurigo nodularis in another phase 2 trial, a second phase 2 trial, LIBERTY-PN PRIME (NCT04183335), was performed to assess the efficacy and safety of dupilumab in prurigo nodularis. The primary study endpoint was the proportion of patients with an ≥4-point improvement (reduction) in their worst itch numerical rating scale (WI-NRS) from baseline to week 24. A clear (0) or almost clear (1–5 prurigo nodularis lesions) outcome in the investigator´s global assessment (IGA) at week 24 was used as a secondary endpoint. All enrolled partici...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on